{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:43:30Z","timestamp":1790419410220,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.semarthrit.2020.02.004","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T11:38:26Z","timestamp":1581593906000},"page":"394-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective"],"prefix":"10.1016","volume":"50","author":[{"given":"Mickael","family":"Hiligsmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setareh A","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine A","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart S","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.semarthrit.2020.02.004_bib0001","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.02.004_bib0002","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jbm4.10041","article-title":"Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy","volume":"2","author":"Leder","year":"2018","journal-title":"JBMR Plus."},{"issue":"49","key":"10.1016\/j.semarthrit.2020.02.004_bib0003","doi-asserted-by":"crossref","first-page":"e5496","DOI":"10.1097\/MD.0000000000005496","article-title":"The effect of sequential therapy for postmenopausal women with osteoporosis: a PRISMA-compliant meta-analysis of randomized controlled trials","volume":"95","author":"Lou","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.02.004_bib0004","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.02.004_bib0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","volume":"30","author":"Hiligsmann","year":"2019","journal-title":"Osteoporos Int."},{"issue":"2","key":"10.1016\/j.semarthrit.2020.02.004_bib0006","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jval.2017.12.009","article-title":"A health economics approach to us value assessment frameworks-summary and recommendations of the ISPOR special task force report","volume":"21","author":"Garrison","year":"2018","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.02.004_bib0007","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jval.2017.12.003","article-title":"ISPOR's initiative on us value assessment frameworks: seeking a role for health economics","volume":"21","author":"Sculpher","year":"2018","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.02.004_bib0008","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semarthrit.2019.01.006","article-title":"Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture","volume":"49","author":"Hiligsmann","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.02.004_bib0009","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1524-4733.2009.00687.x","article-title":"Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence","volume":"13","author":"Hiligsmann","year":"2010","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.02.004_bib0010","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/11539980-000000000-00000","article-title":"Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium","volume":"29","author":"Hiligsmann","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.02.004_bib0011","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1524-4733.2008.00497.x","article-title":"Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis","volume":"12","author":"Hiligsmann","year":"2009","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.02.004_bib0012","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4158\/EP161435.ESGL","article-title":"American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016\u2013Executive summary","volume":"22","author":"Camacho","year":"2016","journal-title":"Endocrine Practice"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.02.004_bib0013","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2020.02.004_bib0014","unstructured":"Academy of Managed Care Pharmacy. The AMCP format for formulary submissions version 4.0. A Format for Submission of Clinical and Economic Evidence in Support of Formulary Consideration. April 2016. Accesshttp:\/\/www.amcp.org\/FormatV4\/."},{"issue":"2","key":"10.1016\/j.semarthrit.2020.02.004_bib0015","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) statement","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.semarthrit.2020.02.004_bib0016","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","article-title":"Osteoporosis in the European Union: a compendium of country-specific reports","volume":"8","author":"Svedbom","year":"2013","journal-title":"Arch Osteoporos"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.02.004_bib0017","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00198-009-1032-9","article-title":"Updated fracture incidence rates for the US version of Frax","volume":"21","author":"Ettinger","year":"2010","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.02.004_bib0018","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"Journal of Bone and Mineral Research"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.02.004_bib0019","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","article-title":"A meta-analysis of previous fracture and subsequent fracture risk","volume":"35","author":"Kanis","year":"2004","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.02.004_bib0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S8756-3282(00)00381-1","article-title":"Risk of hip fracture according to the world health organization criteria for osteopenia and osteoporosis","volume":"27","author":"Kanis","year":"2000","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.02.004_bib0021","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","article-title":"Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis","volume":"15","author":"Klotzbuecher","year":"2000","journal-title":"J Bone Mineral Res"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.02.004_bib0022","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","article-title":"Imminent risk of fracture after fracture","volume":"28","author":"Johansson","year":"2017","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.02.004_bib0023","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.02.004_bib0024","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/jbmr.3118","article-title":"Population-Wide impact of non-hip non-vertebral fractures on mortality","volume":"32","author":"Tran","year":"2017","journal-title":"J Bone Mineral Res"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.02.004_bib0025","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","article-title":"Excess mortality after hospitalisation for vertebral fracture","volume":"15","author":"Kanis","year":"2004","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.02.004_bib0026","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","article-title":"The components of excess mortality after hip fracture","volume":"32","author":"Kanis","year":"2003","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.02.004_bib0027","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1046\/j.1532-5415.2002.50455.x","article-title":"Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study","volume":"50","author":"Leibson","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.semarthrit.2020.02.004_bib0028","series-title":"Consumer price index for all urban consumers: medical care [CPIMEDSL], retrieved from FRED","year":"2017"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.02.004_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2011.02.698","article-title":"Osteoporosis-Related fracture costs among female commercially insured and medicare patients","volume":"14","author":"Bonafede","year":"2011","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.02.004_bib0030","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","article-title":"Cost-effective osteoporosis treatment thresholds: the United States perspective","volume":"19","author":"Tosteson","year":"2008","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.02.004_bib0031","first-page":"461","article-title":"Prevalence and cost of subsequent fractures among U.S. Patients with an Incident Fracture","volume":"23","author":"Weaver","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.semarthrit.2020.02.004_bib0032","unstructured":"Genworth 2017 Cost of Care Survey, conducted by Carescout. long term care costs across the United States; June 2017. https:\/\/www.genworth.com\/about-us\/industry-expertise\/cost-of-care.html"},{"key":"10.1016\/j.semarthrit.2020.02.004_bib0033","unstructured":"WAC price, Online red book, December 2017."},{"issue":"7","key":"10.1016\/j.semarthrit.2020.02.004_bib0034","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2020.02.004_bib0035","unstructured":"The Medicare Learning Network\u00ae, MLN connects\u00ae, and MLN matters\u00ae. The ABCs of the annual wellness visit (AWV). G0349 code."},{"issue":"11","key":"10.1016\/j.semarthrit.2020.02.004_bib0036","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/archinte.166.11.1209","article-title":"The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis","volume":"166","author":"Liu","year":"2006","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.semarthrit.2020.02.004_bib0037","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/rheumatology\/kex430","article-title":"Comment on: patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply","volume":"57","author":"Hiligsmann","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.02.004_bib0038","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","article-title":"Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US","volume":"11","author":"Parthan","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.02.004_bib0039","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/0272989X06290497","article-title":"Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores","volume":"26","author":"Hanmer","year":"2006","journal-title":"Med Decis Mak"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.02.004_bib0040","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00198-017-4317-4","article-title":"Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS","volume":"29","author":"Svedbom","year":"2018","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.02.004_bib0041","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00223-008-9117-6","article-title":"Utility values associated with osteoporotic fracture: a systematic review of the literature","volume":"82","author":"Hiligsmann","year":"2008","journal-title":"Calcif. Tissue Int."},{"issue":"8","key":"10.1016\/j.semarthrit.2020.02.004_bib0042","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.semarthrit.2020.02.004_bib0043","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40273-014-0231-1","article-title":"A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis","volume":"33","author":"Hiligsmann","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.02.004_bib0044","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00198-014-2900-5","article-title":"Residual effect after oral bisphosphonate treatment and healthy adherer effects-the Swedish adherence register analysis (SARA)","volume":"26","author":"Strom","year":"2015","journal-title":"Osteoporosis Int"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.02.004_bib0045","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"NEngl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.02.004_bib0046","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/cer.15.50","article-title":"Cost\u2013effectiveness thresholds in the USA: are they coming? Are they already here?","volume":"5","author":"Dubois","year":"2016","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.semarthrit.2020.02.004_bib0047","series-title":"Decision modelling for health economic evaluation","author":"Briggs","year":"2006"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.02.004_bib0048","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)","volume":"24","author":"Eastell","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.02.004_bib0049","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.02.004_bib0050","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"10117","key":"10.1016\/j.semarthrit.2020.02.004_bib0051","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.semarthrit.2020.02.004_bib0052","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.semarthrit.2020.02.004_bib0053","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220300238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220300238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:00:38Z","timestamp":1758733238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220300238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0049017220300238"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.02.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}